At a glance
- Originator Johnson & Johnson
- Class Antihypertensives
- Mechanism of Action Angiotensin type 1 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Hypertension
Most Recent Events
- 01 Jun 1995 Discontinued-Preclinical for Hypertension in USA (PO)
- 26 Apr 1995 No-Development-Reported for Hypertension in USA (PO)